The Role of Chemotherapy and Immunotherapy in ROS1-Rearranged NSCLC

Next-Generation TKI Therapy for ROS1-Rearranged NSCLC

The Role of Chemotherapy and Immunotherapy in ROS1-Rearranged NSCLC

MinuteCE®
ReachMD Healthcare Image
Media formats available:
Details
Episodes
Documents
Presenters
Comments
  • Overview

    This program aims to raise awareness of approved and emerging targeted therapies and practice guidelines for ROS1+ NSCLC. It is critical to create a greater understanding of the limitations existing agents have with acquired resistance mutations and intracranial penetration and the potential advantage new and emerging agents offer to resolve and evade these challenges.

  • Target Audience

    This activity has been designed to meet the educational needs of the interprofessional team, which includes medical oncologists and pathologists, as well as other healthcare providers, involved in managing patients with NSCLC.

  • Learning Objectives

    After participating in this educational activity, participants should be better able to: 

    • Discuss current guidelines and standards for molecular testing in real-world practice settings
    • Assess the latest evidence of approved ROS1 inhibitors and emerging next-generation TKIs for the treatment of newly diagnosed ROS1-rearranged NSCLC
    • Analyze treatment options for patients with ROS1-rearranged, advanced NSCLC in second or subsequent-line therapy focused on acquired resistance mutations and CNS involvement
    • Evaluate intracranial penetration and activity against acquired resistance mutations seen with ROS1-targeted TKI therapies
    • Evaluate the toxicity profiles of current and emerging ROS1 TKI agents and inform optimal strategies for preventing and mitigating TKI-related adverse events
  • Accreditation Statement

    In support of improving patient care, this activity has been planned and implemented by Global Learning Collaborative (GLC) and Total CME, LLC. GLC is jointly accredited by the American Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.

    This activity was planned by and for the healthcare team, and learners will receive 1.0 Interprofessional Continuing Education (IPCE) credit for learning and change.

  • Disclosure of Relevant Financial Relationships

    Disclosure Policy
    In accordance with the ACCME Standards for Integrity and Independence, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any ineligible company. GLC mitigates all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all educational programs. 

    The following faculty have disclosed:

    Alexander Drilon, MD, faculty for this educational event, receives research grants and manages funds from Foundation, Medicine, Teva, Taiho, GlaxSmithKlein, PharmaMar; receives ownership interest from mBrace; receives royalties for Wolters Kluwer; and receives consulting fees from 14ner/Elevation Oncology, Abbvie, AstraZeneca, Bayer, Boundless Bio, Bristol Myers, Squibb, Boehringer Ingelheim, EcoR1 Capital, LLC, Entos, Ignyta/Genentech/Roche, Innocare, Loxo/Bayer/Lilly, MonteRosa, Novartis, Nuvalent, Regeneron, Springer Healthcare, and Treeline Bio. 

    Charu Aggarwal, MD, MPH, FASCO, faculty for this educational event, receives research grant and manages funds from Genentech/Roche, Incyte, Macrogenics, Merck Sharp & Dohome, AstraZeneca/Medimmune; and receives consulting fees from Genentech, Lilly, Celgene, Merk, Astra Zeneca, Blueprint Genetics, Shionogi, Daiichi Sankyo/Astra Zeneca, Regeneron/Sanofi, Eisai, BeiGene, Turning Point, Pfizer, Janssen, and Boehringer Ingelheim.

  • Planners and Managers Disclosure List

    The following planners/reviewers/managers have disclosed:

    William Mencia, MD, FACEHP, CHCP, reviewer for this educational event, has no relevant financial relationships with ineligible companies.

    Total CME, LLC, planners and managers have no relevant commercial relationships to disclose.

    All the relevant financial relationships for these individuals have been mitigated.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Total CME, LLC. This presentation is not intended to define an exclusive course of patient management; the participant should use their clinical judgment, knowledge, experience, and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient's conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of MedEd On The Go you are subject to the terms and conditions of use, including copyright and licensing restrictions, of that site.

    Reproduction Prohibited
    Reproduction of this material is not permitted without written permission from the copyright owner.

  • Provider(s)/Educational Partner(s)

    Jointly provided by Global Learning Collaborative (GLC) and Total CME, LLC.

  • Commercial Support

    This activity is supported by An independent educational grant from Bristol Myers Squibb.

  • Instructions for Completion

    During the period 3/1/2024 through 3/1/2025, registered participants wishing to receive continuing education credit for this activity must follow these steps:
    1. Read the learning objectives and faculty disclosures.
    2. Answer a pre-program question.
    3. View the program.
    4. Complete the post-test with a score of 100%. 
    5. Complete activity evaluation.
    6. Apply for credit and either bank your credits or print your certificate.

    For Pharmacists: Upon successfully completing the post-test with a score of 100% and the activity evaluation form, transcript information will be sent to the NABP CPE Monitor Service. This may require you to add or update the e-profile ID/date of birth information saved in your account.

  • System Requirements

    Our site requires a computer, tablet, or mobile device and a connection to the Internet. For best results, a high-speed Internet connection is recommended (DSL/Cable/Fibre). We also recommend using the latest version of your favorite browser to ensure compliance with W3C standards, such as Chrome, Safari, Firefox, or Microsoft Edge.

  • Publication Dates

    Release Date:

    Expiration Date:

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free